Filing Details

Accession Number:
0000937556-24-000030
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-04-30 20:11:11
Reporting Period:
2024-04-26
Accepted Time:
2024-04-30 20:11:11
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
937556 Masimo Corp MASI Electromedical & Electrotherapeutic Apparatus (3845) 330368882
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1186476 B Craig Reynolds C/O Masimo Corporation
52 Discovery
Irvine CA 92618
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-04-26 40,000 $23.04 47,406 No 4 M Direct
Common Stock Disposition 2024-04-26 40,000 $136.17 7,406 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (Right to Buy) Disposition 2024-04-26 40,000 $0.00 40,000 $23.04
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
10,000 2015-05-05 2024-05-05 No 4 M Direct
Footnotes
  1. The shares covered by this Form 4 were exercised and sold pursuant to a Rule 10b5-1 Sales Plan dated as of May 17, 2023, which is intended to comply with Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended.
  2. The price reported in Column 4 represents the weighted average sale price per share. The actual sale prices ranged from a low of $135.46 per share to a high of $137.81 per share. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  3. This option was granted on May 5, 2014 and is exercisable as the option vests. This option vested over a five year period, with 20% of the shares subject to the option vesting on each anniversary of the grant date.